Skip to main content
RUNBEN BIOTECHNOLOGY CO., LTD. logo

RUNBEN BIOTECHNOLOGY CO., LTD. — Investor Relations & Filings

Ticker · 603193 ISIN · CNE100006DK5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 269 across all filing types
Latest filing 2024-10-11 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 603193

About RUNBEN BIOTECHNOLOGY CO., LTD.

https://www.runben.com/

Runben Biotechnology Co., Ltd. focuses on the research, development, production, and distribution of personal care and household hygiene solutions. The company’s core product portfolio is categorized into mosquito repellents, infant and child care, and essential oil products. Key offerings include electric mosquito repellent liquids, botanical essential oil patches, and specialized skincare items such as moisturizing creams and cleansing products tailored for sensitive skin. Runben prioritizes the integration of biotechnology with natural formulations to ensure product safety and efficacy. By maintaining a strong emphasis on product innovation and quality control, the company serves a broad consumer base through integrated online and offline sales channels, positioning itself as a provider of health-oriented daily necessities for family environments.

Recent filings

Filing Released Lang Actions
关于首次公开发行限售股上市流通的公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement regarding the listing and circulation of previously restricted shares following the company's initial public offering (IPO). It details the number of shares becoming freely tradable, the shareholders involved, lock-up periods, and compliance with regulatory approvals from the China Securities Regulatory Commission and Shanghai Stock Exchange. The document includes no financial statements or performance data but focuses on share circulation and compliance with lock-up commitments. The document length is 3446 characters, which is relatively short and consistent with an announcement rather than a full report. This fits the definition of a Share Issue/Capital Change announcement, specifically about the release of restricted shares into circulation after an IPO. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2024-10-11 Chinese
关于签署投入产出监管协议暨对外投资的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the signing of an investment and regulatory agreement related to an external investment project by the company. It details the investment amount, project description, risks, and approvals by the board. There are no financial statements, earnings data, or detailed financial analysis present. The document is a formal disclosure of a capital investment decision and related agreements, which fits the category of Capital/Financing Update (CAP). The document length is about 3,079 characters, which is consistent with an announcement rather than a full report. Therefore, the appropriate classification is CAP with high confidence.
2024-09-23 Chinese
第二届董事会第五次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of the resolutions passed at the company's second board of directors' fifth meeting. It details the meeting date, attendance, agenda items, and voting results. The content focuses on board decisions regarding investment and authorization for signing agreements. There is no financial data, earnings information, or detailed report content. It is not a full annual or interim report, nor an earnings release. It is not a proxy statement or voting results announcement. The document is clearly about board/management decisions and meeting resolutions, fitting the category of Board/Management Information (MANG). The document length is short (1055 characters), and it is not an announcement of a report publication but a substantive board meeting resolution announcement.
2024-09-23 Chinese
关于签订募集资金专户存储三方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the signing of a tripartite supervision agreement for the special account storage of raised funds following the company's initial public offering (IPO). It details the agreement's terms, the opening of the special account, and the roles of the company, bank, and sponsor institution. The document does not contain financial statements or performance data but focuses on the regulatory and procedural aspects of managing the raised capital. It is a regulatory announcement about capital management and compliance rather than a financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 2784 characters, which is consistent with an announcement rather than a full report.
2024-09-03 Chinese
2024年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 2024 second extraordinary general meeting of shareholders of Runben Biotechnology Co., Ltd. It details the meeting date, attendance, voting results on profit distribution, and legal witness statements. It does not contain financial statements or detailed financial analysis but reports the voting outcomes and meeting procedures. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is about 2054 characters, consistent with a meeting resolution announcement rather than a full report.
2024-09-02 Chinese
广东广信君达律师事务所关于润本生物技术股份有限公司2024年第二次临时股东大会的法律意见书
Regulatory Filings
2024-09-02 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.